Have Questions? Email support@soracilabs.com
SS-31 and Cardiolipin: Targeting a Lipid, Not a Receptor
Almost every drug-like molecule targets a protein. This one targets the phospholipid that gives cristae their shape.
In short
The SS-31 cardiolipin interaction is unusual for a simple reason: almost every drug-like molecule targets a protein, and this one targets a lipid. SS-31 concentrates in the inner mitochondrial membrane and binds cardiolipin, the phospholipid that gives cristae their shape and holds the respiratory chain together.
What SS-31 is
SS-31 is a tetrapeptide, one of the Szeto-Schiller series, and it is also known by its clinical development name elamipretide. Four residues is very short even by peptide standards.
Its defining structural feature is an alternating aromatic and cationic motif. That pattern makes the molecule cell-permeable without a transporter, which is unusual for something carrying net positive charge.
Cardiolipin: the lipid that SS-31 binds
Cardiolipin is a dimeric phospholipid with four acyl chains rather than the usual two. It is found almost exclusively in the inner mitochondrial membrane, where it makes up a substantial share of the lipid content.
Its roles are structural and functional at once. The four-chain shape favours the membrane curvature that forms cristae, and cardiolipin is required for the assembly of respiratory chain supercomplexes. It also anchors cytochrome c to the membrane.
Because of that, cardiolipin damage is not a side effect of mitochondrial dysfunction so much as a mechanism of it. Peroxidised cardiolipin releases cytochrome c and destabilises the architecture that the electron transport chain depends on.
Why the SS-31 cardiolipin interaction is unusual
Most therapeutics bind a protein: a receptor, an enzyme, a channel. Binding a structural lipid instead means the proposed mechanism is not inhibition or activation in the familiar sense.
Instead, the published model is protective and architectural. SS-31 associates with cardiolipin through combined electrostatic and hydrophobic interactions, and the proposal is that this preserves cristae structure and limits the peroxidase activity of the cytochrome c and cardiolipin complex.
So the compound is described in the literature as cardiolipin-protective rather than as an agonist or antagonist. That distinction matters when designing controls, because there is no receptor to block.
Uptake without a membrane potential
Other mitochondria-targeted molecules reach the matrix by exploiting the membrane potential, typically by carrying a lipophilic cation such as triphenylphosphonium. Those accumulate in proportion to how polarised the membrane is.
SS-31 does not depend on that. It partitions into the inner membrane itself, which means it still reaches damaged mitochondria where the potential has collapsed.
That property is arguably the more interesting one experimentally. A depolarised mitochondrion is exactly the case where potential-dependent agents fail to arrive.
What SS-31 cardiolipin research is testing
Elamipretide has been studied clinically in primary mitochondrial myopathy and in Barth syndrome, a disorder in which cardiolipin remodelling is directly impaired. Trials in those settings have been run and reported; the literature is the place to read outcomes rather than a product page.
In laboratory work the question is usually narrower: whether preserving cardiolipin preserves respiratory function, cristae morphology or supercomplex assembly in a given model.
For how SS-31 compares with the other compounds filed under the same heading, see our guide to NAD+, MOTS-c and SS-31, which sets the three side by side.
Handling notes
SS-31 is supplied lyophilised and reconstitutes readily in aqueous solvent, helped by its cationic residues. Handle it as any short peptide: bacteriostatic water added gently, cold storage, no repeated freeze-thaw.
Its short sequence means fewer of the classic degradation liabilities than a longer peptide carries, but the storage and stability guide still applies.
SS-31 cardiolipin: frequently asked questions
Is SS-31 the same thing as elamipretide?
Yes. SS-31 is the research designation from the Szeto-Schiller peptide series; elamipretide is the name used in clinical development. Both refer to the same tetrapeptide.
Why does binding a lipid matter more than binding a protein?
Because cardiolipin is structural. It shapes cristae, supports respiratory supercomplex assembly and anchors cytochrome c, so protecting it addresses the architecture the electron transport chain sits in rather than any single protein within it.
How does SS-31 get into mitochondria without a transporter?
Its alternating aromatic and cationic motif lets it cross membranes and partition into the inner membrane directly. Critically, that partitioning does not depend on membrane potential, so it still reaches mitochondria that have depolarised.
How is it different from TPP-conjugated mitochondrial compounds?
Triphenylphosphonium-conjugated agents accumulate in proportion to membrane potential, so they concentrate best in healthy, well-polarised mitochondria. SS-31 does not rely on that gradient, which inverts where each is most likely to arrive.
Is there a receptor to antagonise in a control experiment?
No, and that is the design problem. Because the target is a structural lipid rather than a receptor, controls usually rely on cardiolipin-deficient or remodelling-impaired models rather than on a blocking agent.
Related products
SS-31. Related mitochondrial compounds: NAD+ and MOTS-c. Reconstitute with Hospira Bacteriostatic Water 30ml.
References
The sources below are indexed on PubMed, and compound records are held at PubChem.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology — the mechanistic account of the interaction.
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology.
- Paradies G, Paradies V, De Benedictis V, Ruggiero FM, Petrosillo G. Functional role of cardiolipin in mitochondrial bioenergetics. Biochimica et Biophysica Acta — on cristae structure and supercomplex assembly.
Research use only. Every product referenced here is sold strictly for in-vitro laboratory research. Nothing on this page is medical advice, and none of these compounds are approved for human or veterinary use, diagnosis or treatment.
[…] gets a fuller treatment of its own in SS-31 and cardiolipin, which covers why binding a structural lipid rather than a receptor changes how the compound has to […]